|
Venous Thromboembolism
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We suggest that MVs instead of whole EV preparations, and TF activity rather than its antigenic quantification should be used in clinical studies for identifying patients with progressive tumors at high risk for VTE.
|
31734835 |
2020 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, patients anticoagulated with VKA after VTE showed a reduced plasma thrombin generation that was accurately reflected by tissue factor activated ROTEM.
|
30959280 |
2019 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.
|
31223264 |
2019 |
|
Venous Thromboembolism
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Tissue factor overexpression is associated with tumor progression, venous thromboembolism, and worsened survival in patients with cancer.
|
30844808 |
2019 |
|
Venous Thromboembolism
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The association between TF-bearing MPs and the risk of VTE in cancer patients was found in this meta-analysis.
|
29374212 |
2018 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The aim of the present study was to investigate whether the activity of the complement pathways, the level of mannose-binding lectin (MBL) and tissue-factor (TF) induced thrombin generation were associated with risk of unprovoked VTE.
|
30015228 |
2018 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overall, none of the measured biomarkers at any time-point did significantly associate with VTE incidence, although increased total TF at baseline showed significant association in control patients not receiving low molecular weight heparin (P = 0.03).
|
30412630 |
2018 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clotting pathway factors, including TF, may have utility as biomarkers in CRC, for assessment of VTE risk in addition to cancer prognosis.
|
29127473 |
2018 |
|
Venous Thromboembolism
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The tissue factor (TF) gene is one of the most important mediators of coagulation and VTE, but, so far, there are limited data on androgen receptor (AR)-mediated TF gene expression.
|
29427323 |
2018 |
|
Venous Thromboembolism
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Meanwhile, in NSCLC patients with VTE, the expression of monocyte TF mRNA was significantly higher than that in patients without VTE (P < .01).
|
28419722 |
2018 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The occurrence of VTE was evaluated, as were serial changes in parameters measured by the Total Thrombus-formation Analysis System, a novel system for quantitatively analyzing thrombus formation using microchips with thrombogenic surfaces (collagen plus tissue factor, atheroma [AR]-chip).
|
28924075 |
2018 |
|
Venous Thromboembolism
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Levels of MV TF activity were not associated with venous thromboembolism in cancer patients.
|
29539580 |
2018 |
|
Venous Thromboembolism
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The levels of TF were not associated with an increased risk of unprovoked VTE, as compared with controls.
|
30278301 |
2018 |
|
Venous Thromboembolism
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We evaluated an in-house EV-TF activity assay (the fibrin generation test) for the prediction of cancer-associated VTE.
|
29656167 |
2018 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here we hypothesize that elevated factor levels affect the pro- and anticoagulant balance in coagulation such that even minute amounts of tissue factor (TF) will initiate thrombin formation, thereby contributing to the VTE risk.
|
30408635 |
2018 |
|
Venous Thromboembolism
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In pancreatic cancer patients, tumor-derived TF<sup>+</sup> MVs are present in the blood, and increased levels are associated with venous thromboembolism and decreased survival.
|
28834179 |
2017 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Patients in the highest quartile of TF experienced the greatest VTE recurrence (> 64.6 pg/mL; 38 [19%] of 203 patients v 34 [6%] of 602 patients; relative risk, 3.3; 95% CI, 2.1 to 5.1; P < .001).
|
28029329 |
2017 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
: Microvesicles associated with tissue factor (TF) may play a role in cancer-related venous thromboembolism; however, not much is known about their interaction with the tumour stroma, especially the endothelium or any procoagulant changes seen because of this interaction.
|
27841803 |
2017 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although several potential mechanisms for the development of VTE in cancer have been postulated, this review explores the homeostatic disruption of TF-MPs, as the main reservoir of bloodborne TF, in the context of cancer and inflammation, and considers the abrogated responses of the activated endothelium and mononuclear phagocyte system in mediating this disruption.
|
29028284 |
2017 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The effects of MPs on thrombogenesis include the exposure of phopshatidylserine and the expression of tissue factor and MPs have been described in clinical studies as possible diagnostic and prognostic biomarkers for VTE.
|
27816948 |
2017 |
|
Venous Thromboembolism
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Multivariate analysis identified TF expression and pretreatment dimerized plasmin fragment D level as significant independent risk factors for VTE development.
|
27755234 |
2017 |
|
Venous Thromboembolism
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The aim of this study was to investigate the distributions of TF and TFPI polymorphisms in Koreans and to analyze the association of these genetic polymorphisms with plasma levels and development of venous thromboembolism (VTE).
|
24448154 |
2014 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The aim of this study was to measure tumour derived TF and TFPI and to investigate their potential role in VTE in ovarian cancer patients.
|
24094893 |
2013 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cancer histology influences the risk of venous thromboembolism and tissue factor (TF) is the key molecule in cancer-induced hypercoagulability.
|
21917301 |
2012 |
|
Venous Thromboembolism
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To evaluate the possible contribution of elevated blood TF to VTE risk, we performed serial studies of peripheral blood mononuclear cell (PBMC) functional TF procoagulant activity (PCA) in 19 patients after TKA.
|
19806259 |
2009 |